Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | NOS3 | P29474 | 1/20 | 0.30 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
| ▸ | NOS2 | P35228 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL918389 | 0.85 | MAPK1 (0.41) | MAPK1MEN1KMT2ANOS3NOS1 | |
| SCHEMBL1089769 | 0.80 | — | — | |
| SCHEMBL339946 | 0.77 | — | — | |
| SCHEMBL3664749 | 0.77 | — | — | |
| SCHEMBL10934052 | 0.77 | — | — | |
| SCHEMBL10934045 | 0.77 | — | — | |
| SCHEMBL16581378 | 0.76 | MEN1 (0.41) | MAPK1MEN1KMT2A | |
| SCHEMBL1073565 | 0.71 | — | — | |
| SCHEMBL1047817 | 0.70 | MAPT (0.41) | MAPK1KMT2ANOS3NOS1NOS2 | |
| SCHEMBL16253822 | 0.70 | NOS3 (0.31) | NOS3NOS1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115551825-A | Lilac type aromatic compound | 西姆莱斯有限公司 | 2022-12-30 | — | — | CN | disclosed |
| EP-1871776-A2 | FUSED THIENO[2,3-B]PYRIDINE AND THIAZOLO[5,4-B]PYRIDINE COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY | SCHERING CORPORATION (US) | 2008-01-02 | — | — | EP | disclosed |
| US-20060247320-A1 | Compounds for inhibiting KSP kinesin activity | SCHERING CORPORATION | 2006-11-02 | — | — | US | disclosed |
| WO-2006098961-A2 | FUSED THIENO [2, 3-B] PYRIDINE AND THIAZOLO [5, 4-B] PYRIDINE COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY | SCHERING CORPORATION (US) | 2006-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247320-A1 | Compounds for inhibiting KSP kinesin activity | KIFC1, KIF5B, KIF2C | MAPK1 1014/4885CRBN 1944/4885MEN1 1880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.